Growth hacking

Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia

Retrieved on: 
Tuesday, August 23, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CRC, ECG, FMS, Technology, Safety, Pharmacokinetics, Stem cell, European Hematology Association, Leukemia, CHMP, Adult, Risk, Congress, Patient, Cardiovascular disease, EMA, TSE, Cancer, Survival, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, OS, AML, Incidence, Food, University, Sustainable development, FLT3, CD135, American Cancer Society, Fast track (FDA), HSCT, R, MAA, Daiichi Sankyo, Quality of life, Acute myeloid leukemia, MD, Mutation, Growth, Review, Marketing, EFS, Cytarabine, European Medicines Agency, MD Anderson Cancer Center, Orphan, Diagnosis, Prognosis, QT, Growth hacking, Validation, European Directive on Traditional Herbal Medicinal Products, Health insurance, Pharmaceutical industry, Wood drying

We look forward to working with the EMA to support their review of quizartinib as a potential option for patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia.

Key Points: 
  • We look forward to working with the EMA to support their review of quizartinib as a potential option for patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia.
  • The application is based on data from the QuANTUM-First phase 3 trial recently presented at the European Hematology Association (#EHA2022) Congress.
  • Patients were randomized 1:1 into two treatment groups to receive quizartinib or placebo combined with anthracycline- and cytarabine-based regimens.
  • Quizartinib is currently approved for use in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD AML, as detected by an approved test.

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Retrieved on: 
Monday, August 22, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Inflammation, COVID-19, NDA, Technology, Tablet, Survival, Amyotrophic lateral sclerosis, Central nervous system, File, Cognition, Toxicity, Disease, Gemstone, Volunteering, Advertising, ACOG, Forward-looking statement, ER, TSX, Alzheimer's disease, Growth hacking, Rivastigmine, IR, OTC Markets Group, MD, Galantamine, Donepezil, Company, FDA, Neurodegeneration, Memantine, News, Failure, Adult, TSX Venture Exchange, AD, Terminology, Growth, Industry, Capsule, ALS, Patient, Pharmaceutical industry, Generic drug, Cmax

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimers Disease (AD).

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimers Disease (AD).
  • After a one-week washout period, subjects were then crossed over to the other treatment arm and dosed for 7 days.
  • Topline results confirmed that in healthy adult volunteers treated to steady state, ALPHA-1062 was bioequivalent to galantamine hydrobromide ER.
  • Cedric OGorman, MD, Chief Medical Officer of Alpha Cognition, commented, "We are delighted with these additional positive registrational bioequivalence results from our second study of our lead asset, ALPHA-1062, which further strengthens our NDA filing.

Brighthouse Financial Expands Flagship Shield Level Annuity Suite With New Product That Provides Guaranteed Lifetime Income

Retrieved on: 
Monday, August 8, 2022
Personal Finance, Professional Services, Insurance, Finance, FINRA, Income, Social, Medicare, Prospectus, Social Security Administration, LLC, Marketing, Guaranteed, View, Retirement, Partnership, Â, Shield, Lifetime income tax, Social Security, Goal, Growth hacking, Brighthouse Financial, Longevity, Alliance, Life insurance, Insurance, Financial adviser, Bright House

The financial impact of longevity has made guaranteed lifetime income an important consideration for retirees who want to help secure their financial future, said Myles Lambert, chief distribution and marketing officer, Brighthouse Financial.

Key Points: 
  • The financial impact of longevity has made guaranteed lifetime income an important consideration for retirees who want to help secure their financial future, said Myles Lambert, chief distribution and marketing officer, Brighthouse Financial.
  • Brighthouse Financial specifically designed Shield Level Pay Plus annuities to help meet the need for reliable retirement income, and we are very pleased to add this new product to our suite of Shield Level annuities, concluded Lambert.
  • Brighthouse Shield Level Pay Plus Annuity and Brighthouse Shield Level Pay Plus Advisory Annuity, collectively referred to as Shield Level Pay PlusSM annuities, are part of the Shield annuity suite of single premium deferred index-linked annuity products that are referred to as Shield Level annuities or Shield annuities.
  • Brighthouse Shield Level Pay PlusSM Annuity and Brighthouse Shield Level Pay PlusSM Advisory Annuity, collectively referred to as Shield Level Pay PlusSM annuities, are index-linked annuities issued by, and product guarantees are solely the responsibility of, Brighthouse Life Insurance Company, Charlotte, NC 28277, on Policy Form L-22494 (09/12)-AV (Brighthouse Financial).

Global Vaporizers Market Report 2022: Featuring Key Players Vicks, Vanker, GE Healthcare & Others - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Medical Devices, Health, ECC, Vaporizer (inhalation device), Application, Technology, European Medical Writers Association, Growth, GE Healthcare, THC, Market share, Growth hacking, Water, Electricity, Distribution, Heat, Mighty, Temperature, Renewable energy

The "Global Vaporizers Market Report 2022, by Type, by Application, by Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vaporizers Market Report 2022, by Type, by Application, by Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • The vaporizers market consists of sales of vaporizers.
  • The main types of vaporizers market are e-cigarette vaporizers, marijuana vaporizers, medical vaporizers.
  • Growing advancements in vaporizers are driving the growth of the vaporizers market.

Corporate E-learning Market: Maximum Growth to Come from India and Japan of APAC, By End-user (services, manufacturing, retail, and others), Deployment, and Geography

Retrieved on: 
Wednesday, August 3, 2022
Geography, Organization, USD, CAGR, Growth hacking, THIS, International Relief and Development Inc., Adobe Inc., Industry, Segment, Growth, Solution, Corporation, Revenue, MEA, Retail, Telecommunication

The corporate e-learning market is fragmented, and the vendors are deploying growth strategies such asorganic and inorganic strategiesto compete in the market.

Key Points: 
  • The corporate e-learning market is fragmented, and the vendors are deploying growth strategies such asorganic and inorganic strategiesto compete in the market.
  • Corporate E-learning Market Geography Outlook (Revenue, USD bn, 2020-2025)
    40% of the market's growth will originate from APACduring the forecast period.
  • Market growth in this region will be fasterthan the growth of the market in other regions.
  • The corporate training market report also offers information on several market vendors, including Adobe Inc., Berlitz Corp., Blanchard Training and Development Inc., and more

Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Chromosome Instability during Culture of Induced Pluripotent Stem Cells

Retrieved on: 
Thursday, July 21, 2022
Gene expression, Time, GLOBE, Genomics, Lineagen, Genome, Regenerative medicine, OGM, U.S. Securities and Exchange Commission, SVS, Doctor of Philosophy, Forward-looking statement, SAN, Culture, Research, IPSC, Growth hacking, Pharmacy, Solution, Software, Private Securities Litigation Reform Act, Lists of diseases, COVID-19, Cancer, Cytogenetics, Adoption, Drug development, Company, Hospital Insurance and Diagnostic Services Act, Patient, Security (finance), Nasdaq, Biology, Autism, Annual report, Gene editing, B cell, Medicine, Pharmaceutical industry, Gene

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term culturing.

Key Points: 
  • SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term culturing.
  • In the study, published in Genes, the authors followed two cell lines over 150 days of continuous culture, or 50 passages, and found significant changes to the genome in both using OGM.
  • Bionano is expanding into markets where OGM is an alternative workflow for cytogenetics in genetic diseases and cancer.
  • In addition, we are driving adoption of OGM into the academic research community to enable novel discoveries connected to structural variations.

Significant Maiden Molybdenum Resource Defined Adjacent to the Tungsten Orebody at Sangdong Mine in South Korea

Retrieved on: 
Monday, July 18, 2022
Mining, Minerals, Natural Resources, Slate, THE, Growth hacking, Person, Competent person, Communication, Tungsten, IS, Nature, Mining, Competence, Glass, Mineral resource estimation, QA/QC, ICP, Forward-looking statement, TSX, Resource management, ANY, LE, QA, Los Santos mine, CRMS, OF, Collection, Risk, Korea Tungsten Company, Compressed air, Molybdenum, Microsoft Excel, Terminology, Wardrop, Acquisition, AKM, Database, KTMC, APT, UPDATE, Molybdenum disulfide, THIS, Element, Sale, OTL, SMS, Jangsan, Uranium, Rare-earth element, Silviculture, Risk management, Panasqueira, WMC, Almonty Industries, Quartzite

This formation contains the Sangdong Molybdenum Stockwork (SMS), a zone of quartz veins hosting predominantly molybdenum mineralisation (Kuehnbaum, 2006 and Le, 2001).

Key Points: 
  • This formation contains the Sangdong Molybdenum Stockwork (SMS), a zone of quartz veins hosting predominantly molybdenum mineralisation (Kuehnbaum, 2006 and Le, 2001).
  • It is currently considered that the deep molybdenum mineralisation is likely to comprise a system of sheeted or stockwork veins.
  • In previous evaluation work, a mineralised envelope had been defined which terminated upwards at the top of the quartzite.
  • The OTL drilling which intersected the area of molybdenum mineralisation, covers 4,000m over 6 holes.

WIMI Hologram Academy: Collision Detection Algorithm Based on Virtual Reality Technology

Retrieved on: 
Thursday, July 7, 2022
Cloud, Efficiency, Cell, Virtual reality, Artificial intelligence, Science, Thought, C1, Pressure, Projection, Research, RADIUS, GLOBE, Tree, Classification, Motion, FDH, Element, Industry, OBB, Growth hacking, R2, Partnership, Environment, Technology, AABB, CPU, Animation, WIMI, NASDAQ, GPU, Time, Computer graphics, AI, C2, Algorithm, Computer simulation, Instrumentation, Road, Computer data storage

Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc.(NASDAQ: WIMI), discussed overall classification and corresponding applicable scenarios for collision detection algorithms.

Key Points: 
  • Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc.(NASDAQ: WIMI), discussed overall classification and corresponding applicable scenarios for collision detection algorithms.
  • This paper expounds on the overall classification of collision detection algorithms, focusing on the graph-based real-time collision detection algorithm most commonly used in virtual reality technology.
  • Dynamic collision detection algorithm can be divided into discrete collision detection algorithm and continuous collision detection algorithm.
  • However, because the real-time detection process is the basic requirement of virtual reality technology applications, so the discrete collision detection algorithm is still the focus and hotspot of collision detection algorithm research.

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Retrieved on: 
Wednesday, June 22, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Time, Rivastigmine, Amyotrophic lateral sclerosis, Vomiting, Industry, FDA, NDA, COVID-19, Stomach, Cognition, TSX, Inflammation, OTC Markets Group, Technology, Survival, Company, Corporation, Donepezil, Alzheimer's disease, Insomnia, Galantamine, Neurodegeneration, Growth, Disease, MD, Central nervous system, Advertising, University, Failure, Fed, Diarrhea, News, Memantine, TSX Venture Exchange, Patient, AD, Terminology, ACOG, Growth hacking, Toxicity, Nausea, ALS, Gemstone, Division, Pharmaceutical industry, Dietary supplement, Neurology

With these positive pivotal study results, Alpha Cognition plans to file an NDA for ALPHA-1062 in mild to moderate AD in Q2 2023.

Key Points: 
  • With these positive pivotal study results, Alpha Cognition plans to file an NDA for ALPHA-1062 in mild to moderate AD in Q2 2023.
  • Cedric OGorman, MD, Chief Medical Officer of Alpha Cognition, commented, We are very pleased with the positive results from the current studies of our lead asset, ALPHA-1062.
  • If approved by the FDA, ALPHA-1062 could provide an exciting next-generation treatment option for patients living with Alzheimers Disease.
  • The Alpha Cognition management team will hold a conference call to discuss the Companys top line results and outlook at 8:00 a.m.

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Rivastigmine, Amyotrophic lateral sclerosis, Industry, FDA, COVID-19, Cognition, TSX, Neuron, OTC Markets Group, Technology, Motor neuron disease, Company, Neurodegeneration, Donepezil, Alzheimer's disease, Growth, Disease, Central nervous system, Advertising, Failure, News, European Patent Office, Memantine, TSX Venture Exchange, Organic acid, Patient, Terminology, IP, ACOG, Growth hacking, European Patent Convention, ALS, Pharmaceutical industry

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents.
  • This claim scope complements the granted European patent EP2249861 directed to treatment of Alzheimers and Parkinsons Disease with progranulin polypeptides and nucleic acids.
  • The successful defense of EP3009143 further supports ACOGs exclusively licensed IP portfolio relating to Progranulin, which includes granted patents and pending applications in Canada, China, India, Japan and the United States.
  • The issued patents demonstrate our commitment to developing ALPHA-0602, which is currently in pre-clinical studies for potential treatment of the motor neuron degeneration associated with ALS, said Michael McFadden, Chief Executive Officer of Alpha Cognition.